Skip to content

BioCryst Pharmaceuticals BCRX Stock issued for employee stock purchase plan

Stock issued for employee stock purchase plan at other companies

Zymeworks logo
ZymeworksZYME
$649K-10.4%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's stock issued for employee stock purchase plan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's stock issued for employee stock purchase plan?
BioCryst Pharmaceuticals (BCRX) reported stock issued for employee stock purchase plan of $1.11M in Q1 2026.
How has BioCryst Pharmaceuticals's stock issued for employee stock purchase plan changed year-over-year?
BioCryst Pharmaceuticals's stock issued for employee stock purchase plan decreased by 8.5% year-over-year, from $1.22M to $1.11M.
What does stock issued for employee stock purchase plan mean?
The value of common stock issued to employees through participation in an employee stock purchase plan (ESPP). This metric indicates the level of employee participation in equity ownership and the associated dilution impact on existing shareholders.